Detalles de la búsqueda
1.
Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP.
Antimicrob Agents Chemother
; : e0147523, 2024 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38709006
2.
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
Antimicrob Agents Chemother
; 67(4): e0005323, 2023 04 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36995219
3.
HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention.
J Infect Dis
; 226(12): 2170-2180, 2022 12 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36240386
4.
Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305).
AIDS Behav
; 26(12): 4107-4114, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35687192
5.
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
PLoS Med
; 15(11): e1002690, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30408115
6.
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.
Ann Intern Med
; 167(6): 384-393, 2017 Sep 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-28828489
7.
Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).
J Infect Dis
; 215(2): 238-246, 2017 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27811319
8.
African Tick Bite Fever Treated Successfully With Rifampin in a Patient With Doxycycline Intolerance.
Clin Infect Dis
; 65(9): 1582-1584, 2017 Oct 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-28505276
9.
HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.
J Int AIDS Soc
; 27(5): e26252, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38783534
10.
Variation in Preferences for Long-Acting Injectable Pre-Exposure Prophylaxis Among US Men Who Have Sex with Men: A Latent Class Analysis.
AIDS Patient Care STDS
; 37(10): 495-503, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37862078
11.
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
Lancet HIV
; 10(12): e767-e778, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37952550
12.
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial.
Lancet HIV
; 10(11): e703-e712, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37783219
13.
Correction to "Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study".
ACS Pharmacol Transl Sci
; 4(4): 1462, 2021 Aug 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35783008
14.
Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study.
ACS Pharmacol Transl Sci
; 4(1): 226-239, 2021 Feb 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33615175
15.
Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077.
J Acquir Immune Defic Syndr
; 85(1): 93-97, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32452972
16.
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.
Lancet HIV
; 7(7): e472-e481, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32497491
17.
The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients.
HIV Clin Trials
; 9(1): 61-72, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18215983
18.
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
HIV Clin Trials
; 19(4): 129-138, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30445896
19.
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
Lancet HIV
; 4(8): e331-e340, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28546090
20.
Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.
AIDS
; 30(8): 1229-38, 2016 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26854810